International Journal of Scientific Research in Dental and Medical Sciences

International Journal of Scientific Research in Dental and Medical Sciences

Clinical Outcome of Combinations of Endocrine Therapy with Targeted Therapy in Women with HR +/ HER2 - Postmenopausal Advanced Breast Cancer: A Systematic Review and Meta-analysis

Document Type : Review Article

Authors
Anahita Shirvani 1
Sheida Sabbagh Seddigh 2
Mahshid Haddad 3
Farzad Amiri 4
Faezeh Fattahi 5
Ebrahim Alipour Limaee 6
1 Department of General Surgery, Imam Khomeini Shahriar Hospital, Tehran, Iran
2 School of Medicine, Faculdade de Medicina da Universidade do Porto-FMUP, Porto, Portugal
3 Independent Researcher, Tehran, Iran
4 Department of Endocrinology and Diabetes, Faculty of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran
5 Department of Obstetrics and Gynecology, Faculty of Medicine, Iran University of Medical Sciences, Tehran, Iran
6 School of Medicine, Iran University of Medical Sciences, Tehran, Iran
10.30485/ijsrdms.2024.458530.1582
Abstract
Background and aim: Breast cancer is one of the most common and worrying health problems of women in the world. The efficacy and safety of first-line and second-line/next-line treatments in women with HR + / HER2 − postmenopausal advanced breast cancer is unclear. Therefore, the present study aimed to determine progression-free survival and overall survival of endocrine therapy combinations with targeted therapy in this population.
Material and methods: To obtain documentation and scientific evidence related to the first and second line/further line in the treatment of postmenopausal women with HR +/ HER2 - advanced breast cancer, articles published in international databases such as PubMed, Web of Science, Scopus, Sites Direct, Elsevier, Wiley, and Google Scholar search engine were used. Data were analyzed using STATA software, Version 17. the odds ratio, hazard ratio, and risk ratio with 95% confidence interval (CI), fixed effect model, and inverse–variance method were used.
Results: Twenty-four studies were reviewed. Abemaciclib/Letrozole showed the best PFS in first-line therapies (HR:0.51 95% CI -2.26, 3.28). Dalpiciclib/Fulvestrant showed the best PFS in second/further-line therapies(HR:0.43 95% CI 0.09, 0.77). Ribociclib/Fulvestrant improved overall survival by 0.67 (HR:0.67 95% CI -0.31, 1.65) for first-line treatments, and Abemaciclib/Fulvestrant improved overall survival for second/further-line treatments65 (HR:0.65 95% CI 0.10, 1.20).
Conclusions: Based on the findings of the present study, superior efficiency can be seen in first-line treatment with combinations of endocrine therapy with targeted therapy.
Keywords
Breast Neoplasms
ERBB2 Protein
Humans
Postmenopausal

Subjects

[1] Coughlin SS. Epidemiology of breast cancer in women. Breast Cancer Metastasis and Drug Resistance: Challenges and Progress. 2019:9-29. https://doi.org/10.1007/978-3-030-20301-6_2.
[2] Arnold M, Morgan E, Rumgay H, Mafra A, Singh D, Laversanne M, et al. Current and future burden of breast cancer: Global statistics for 2020 and 2040. The Breast. 2022;66:15-23. https://doi.org/10.1016/j.breast.2022.08.010.
[3] Cuthrell KM, Tzenios N. Breast Cancer: Updated and Deep Insights. International Research Journal of Oncology. 2023;6(1):104-18.
[4] Dickson RB, Lippman ME. Growth factors in breast cancer. Endocrine reviews. 1995;16(5):559-89. https://doi.org/10.1210/edrv-16-5-559.
[5] Giaquinto AN, Sung H, Miller KD, Kramer JL, Newman LA, Minihan A, et al. Breast cancer statistics, 2022. CA: a cancer journal for clinicians. 2022;72(6):524-41. https://doi.org/10.3322/caac.21754.
[6] Mouabbi JA, Raghavendra AS, Bassett RL, Hassan A, Tripathy D, Layman RM. Survival Outcomes in Patients With Hormone Receptor–Positive Metastatic Breast Cancer With Low or No ERBB2 Expression Treated With Targeted Therapies Plus Endocrine Therapy. JAMA Network Open. 2023;6(5):e2313017. https://doi.org/10.1001/jamanetworkopen.2023.13017.
[7] Mouabbi JA, Osborne CK, Schiff R, Rimawi MF. Management of hormone receptor–positive, human epidermal growth factor 2–negative metastatic breast cancer. Breast Cancer Research and Treatment. 2021:189-201. https://doi.org/10.1007/s10549-021-06383-5.
[8] Bian L, Xu FR, Jiang ZF. Endocrine therapy combined with targeted therapy in hormone receptor-positive metastatic breast cancer. Chinese medical journal. 2020;133(19):2338-45.
[9] Cao LQ, Sun H, Xie Y, Patel H, Bo L, Lin H, et al. Therapeutic evolution in HR+/HER2-breast cancer: from targeted therapy to endocrine therapy. Frontiers in Pharmacology. 2024;15:1340764. https://doi.org/10.3389/fphar.2024.1340764.
[10] Montagna E, Colleoni M. Hormonal treatment combined with targeted therapies in endocrine-responsive and HER2-positive metastatic breast cancer. Therapeutic Advances in Medical Oncology. 2019;11:1758835919894105. https://doi.org/10.1177/1758835919894105.
[11] Rossi V, Berchialla P, Giannarelli D, Nisticò C, Ferretti G, Gasparro S, et al. Should all patients with HR-positive HER2-negative metastatic breast cancer receive CDK 4/6 inhibitor as first-line based therapy? A network meta-analysis of data from the PALOMA 2, MONALEESA 2, MONALEESA 7, MONARCH 3, FALCON, SWOG and FACT trials. Cancers. 2019;11(11):1661. https://doi.org/10.3390/cancers11111661.
[12] Ji D, Luo Y, Wang J, Chen S, Lan B, Ma F, et al. CDK4/6 inhibitors, PI3K/mTOR inhibitors, and HDAC inhibitors as second-line treatments for hormone receptor-positive, HER2-negative advanced breast cancer: a network meta-analysis. BMC cancer. 2023;23(1):805. https://doi.org/10.1186/s12885-023-11290-7.
[13] Giuliano M, Schettini F, Rognoni C, Milani M, Jerusalem G, Bachelot T, et al. Endocrine treatment versus chemotherapy in postmenopausal women with hormone receptor-positive, HER2-negative, metastatic breast cancer: a systematic review and network meta-analysis. The Lancet Oncology. 2019;20(10):1360-9. https://doi.org/10.1016/S1470-2045(19)30420-6.
[14] Minozzi S, Cinquini M, Gianola S, Gonzalez-Lorenzo M, Banzi R. The revised Cochrane risk of bias tool for randomized trials (RoB 2) showed low interrater reliability and challenges in its application. Journal of clinical epidemiology. 2020;126:37-44. https://doi.org/10.1016/j.jclinepi.2020.06.015.
[15] Mayer EL, Ren Y, Wagle N, Mahtani R, Ma C, DeMichele A, et al. PACE: A Randomized Phase II Study of Fulvestrant, Palbociclib, and Avelumab After Progression on Cyclin-Dependent Kinase 4/6 Inhibitor and Aromatase Inhibitor for Hormone Receptor–Positive/Human Epidermal Growth Factor Receptor–Negative Metastatic Breast Cancer. Journal of Clinical Oncology. 2024:JCO-23. https://doi.org/10.1200/JCO.23.01940.
[16] Mayer EL, Ren Y, Wagle N, Mahtani R, Ma C, DeMichele A, et al. Abstract Gs3-06: Gs3-06 Palbociclib after Cdk4/6I and endocrine therapy (PACE): A randomized phase II study of Fulvestrant, Palbociclib, and Avelumab for endocrine pre-treated ER+/Her2-metastatic breast cancer. Cancer Research. 2023;83(5_Supplement):GS3-06. https://doi.org/10.1158/1538-7445.SABCS22-GS3-06.
[17] Howell SJ, Casbard A, Carucci M, Ingarfield K, Butler R, Morgan S, et al. Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive, HER2-negative breast cancer (FAKTION): overall survival, updated progression-free survival, and expanded biomarker analysis from a randomised, phase 2 trial. The Lancet Oncology. 2022;23(7):851-64. https://doi.org/10.1016/S1470-2045(22)00284-4.
[18] Xu B, Zhang QY, Zhang P, Tong Z, Sun T, Li W, et al. LBA16 Dalpiciclib plus letrozole or anastrozole as first-line treatment for HR+/HER2-advanced breast cancer (DAWNA-2): A phase III trial. Annals of Oncology. 2022;33:S1384-5. https://doi.org/10.1016/j.annonc.2022.08.010.
[19] Zhang P, Zhang QY, Hu X, Li W, Tong Z, Sun T, et al. 229P Dalpiciclib plus fulvestrant in HR+/HER2− advanced breast cancer (ABC): Updated analysis from the phase III DAWNA-1 trial. Annals of Oncology. 2022;33:S642-3. https://doi.org/10.1016/j.annonc.2022.07.268.
[20] Goetz MP, Toi M, Huober J, Sohn J, Tredan O, Park IH, et al. LBA15 MONARCH 3: Interim overall survival (OS) results of abemaciclib plus a nonsteroidal aromatase inhibitor (NSAI) in patients (pts) with HR+, HER2-advanced breast cancer (ABC). Annals of oncology. 2022;33:S1384. https://doi.org/10.1016/j.annonc.2022.08.009.
[21] Hortobagyi GN, Stemmer SM, Burris HA, Yap YS, Sonke GS, Hart L, et al. Overall survival with ribociclib plus letrozole in advanced breast cancer. New England Journal of Medicine. 2022;386(10):942-50. https://doi.org/10.1056/NEJMoa2114663.
[22] Xu B, Hu X, Li W, Sun T, Shen K, Wang S, et al. Palbociclib plus letrozole versus placebo plus letrozole in Asian postmenopausal women with oestrogen receptor–positive/human epidermal growth factor receptor 2–negative advanced breast cancer: Primary results from PALOMA-4. European Journal of Cancer. 2022;175:236-45. https://doi.org/10.1016/j.ejca.2022.08.012.
[23] Finn RS, Rugo HS, Dieras VC, Harbeck N, Im SA, Gelmon KA, et al. Overall survival (OS) with first-line palbociclib plus letrozole (PAL+ LET) versus placebo plus letrozole (PBO+ LET) in women with estrogen receptor–positive/human epidermal growth factor receptor 2–negative advanced breast cancer (ER+/HER2− ABC): Analyses from PALOMA-2. 2022;40(17). https://doi.org/10.1200/JCO.2022.40.17_suppl.LBA1003.
[24] Cristofanilli M, Rugo HS, Im SA, Slamon DJ, Harbeck N, Bondarenko I, et al. Overall survival with palbociclib and fulvestrant in women with HR+/HER2− ABC: updated exploratory analyses of PALOMA-3, a double-blind, phase III randomized study. Clinical Cancer Research. 2022;28(16):3433-42. https://doi.org/10.1158/1078-0432.CCR-22-0305.
[25] Xu B, Zhang Q, Zhang P, Hu X, Li W, Tong Z, et al. Dalpiciclib or placebo plus fulvestrant in hormone receptor-positive and HER2-negative advanced breast cancer: a randomized, phase 3 trial. Nature medicine. 2021;27(11):1904-9. https://doi.org/10.1038/s41591-021-01562-9.
[26] Slamon DJ, Neven P, Chia S, Jerusalem G, De Laurentiis M, Im S, et al. Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival. Annals of oncology. 2021;32(8):1015-24. https://doi.org/10.1016/j.annonc.2021.05.353.
[27] Neven P, Johnston SR, Toi M, Sohn J, Inoue K, Pivot X, et al. MONARCH 2: subgroup analysis of patients receiving abemaciclib plus fulvestrant as first-line and second-line therapy for HR+, HER2−-advanced breast cancer. Clinical Cancer Research. 2021;27(21):5801-9. https://doi.org/10.1158/1078-0432.CCR-20-4685.
[28] Llombart-Cussac A, Pérez-García JM, Bellet M, Dalenc F, Gil-Gil M, Ruíz-Borrego M, et al. Fulvestrant-palbociclib vs letrozole-palbociclib as initial therapy for endocrine-sensitive, hormone receptor–positive, ERBB2-negative advanced breast cancer: a randomized clinical trial. JAMA oncology. 2021;7(12):1791-9. https://doi.org/10.1001/jamaoncol.2021.4301.
[29] André F, Ciruelos EM, Juric D, Loibl S, Campone M, Mayer IA, et al. Alpelisib plus fulvestrant for PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor-2–negative advanced breast cancer: Final overall survival results from SOLAR-1. Annals of Oncology. 2021;32(2):208-17. https://doi.org/10.1016/j.annonc.2020.11.011.
[30] Sledge GW, Toi M, Neven P, Sohn J, Inoue K, Pivot X, Burdaeva O, Okera M, Masuda N, Kaufman PA, Koh H. The effect of abemaciclib plus fulvestrant on overall survival in hormone receptor–positive, ERBB2-negative breast cancer that progressed on endocrine therapy MONARCH 2: a randomized clinical trial. JAMA oncology. 2020;6(1):116-24. https://doi.org/10.1001/jamaoncol.2019.4782.
[31] Finn RS, Boer K, Bondarenko I, Patel R, Pinter T, Schmidt M, Shparyk YV, Thummala A, Voitko N, Bananis E, McRoy L. Overall survival results from the randomized phase 2 study of palbociclib in combination with letrozole versus letrozole alone for first-line treatment of ER+/HER2− advanced breast cancer (PALOMA-1, TRIO-18). Breast cancer research and treatment. 2020;183:419-28. https://doi.org/10.1007/s10549-020-05755-7.
[32] Rugo HS, Finn RS, Diéras V, Ettl J, Lipatov O, Joy AA, Harbeck N, Castrellon A, Iyer S, Lu DR, Mori A. Palbociclib plus letrozole as first-line therapy in estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer with extended follow-up. Breast cancer research and treatment. 2019;174:719-29. https://doi.org/10.1007/s10549-018-05125-4.
[33] André F, Ciruelos E, Rubovszky G, Campone M, Loibl S, Rugo HS, Iwata H, Conte P, Mayer IA, Kaufman B, Yamashita T. Alpelisib for PIK3CA-mutated, hormone receptor–positive advanced breast cancer. New England Journal of Medicine. 2019;380(20):1929-40. https://doi.org/10.1056/NEJMoa1813904.
[34] Turner NC, Slamon DJ, Ro J, Bondarenko I, Im SA, Masuda N, Colleoni M, DeMichele A, Loi S, Verma S, Iwata H. Overall survival with palbociclib and fulvestrant in advanced breast cancer. New England journal of medicine. 2018;379(20):1926-36. https://doi.org/10.1056/NEJMoa1810527.
[35] Hortobagyi GN, Stemmer SM, Burris HA, Yap YS, Sonke GS, Paluch-Shimon S, Campone M, Petrakova K, Blackwell KL, Winer EP, Janni W. Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer. Annals of Oncology. 2018;29(7):1541-7. https://doi.org/10.1093/annonc/mdy155.
[36] Goetz MP, Toi M, Campone M, Sohn J, Paluch-Shimon S, Huober J, Park IH, Trédan O, Chen SC, Manso L, Freedman OC. MONARCH 3: abemaciclib as initial therapy for advanced breast cancer. Journal of Clinical Oncology. 2017;35(32):3638-46. https://doi.org/10.1200/JCO.2017.75.6155.
[37] Turner NC, Ro J, André F, Loi S, Verma S, Iwata H, Harbeck N, Loibl S, Huang Bartlett C, Zhang K, Giorgetti C. Palbociclib in hormone-receptor–positive advanced breast cancer. New England Journal of Medicine. 2015;373(3):209-19. https://doi.org/10.1056/NEJMoa1505270.
[38] Tian F, Zhang S, Liu C, Han Z, Liu Y, Deng J, Li Y, Wu X, Cai L, Qin L, Chen Q. Protein analysis of extracellular vesicles to monitor and predict therapeutic response in metastatic breast cancer. Nature communications. 2021;12(1):2536. https://doi.org/10.1038/s41467-021-22913-7.
[39] Fan L, Wang ZH, Ma LX, Wu SY, Wu J, Yu KD, Sui XY, Xu Y, Liu XY, Chen L, Zhang WJ. Optimising first-line subtyping-based therapy in triple-negative breast cancer (FUTURE-SUPER): a multi-cohort, randomised, phase 2 trial. The Lancet Oncology. 2024;25(2):184-97. https://doi.org/10.1016/S1470-2045(23)00579-X.
[40] Han Y, Wang J, Xu B. Clinicopathological characteristics and prognosis of breast cancer with special histological types: a surveillance, epidemiology, and end results database analysis. The Breast. 2020;54:114-20. https://doi.org/10.1016/j.breast.2020.09.006.
[41] Arora S, Narayan P, Osgood CL, Wedam S, Prowell TM, Gao JJ, Shah M, Krol D, Wahby S, Royce M, Ghosh S. US FDA drug approvals for breast cancer: A decade in review. Clinical Cancer Research. 2022;28(6):1072-86. https://doi.org/10.1158/1078-0432.CCR-21-2600.
[42] Yang F, Xiao Y, Ding JH, Jin X, Ma D, Li DQ, Shi JX, Huang W, Wang YP, Jiang YZ, Shao ZM. Ferroptosis heterogeneity in triple-negative breast cancer reveals an innovative immunotherapy combination strategy. Cell metabolism. 2023;35(1):84-100. https://doi.org/10.1016/j.cmet.2022.09.021.
International Journal of Scientific Research in Dental and Medical Sciences
Volume 6, Issue 2
Spring 2024
Pages 74-84

  • Receive Date 25 March 2024
  • Revise Date 03 May 2024
  • Accept Date 21 May 2024
  • Publish Date 01 June 2024